NR4A1 and uterine corpus sarcoma: The Italian Consensus Conference on Management of Uterine Sarcomas in 2020 affirmed that hormonal adjuvant treatment can be offered to patients with uterine AS without sarcomatous overgrowth when hormone receptors are present (11).